Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. TFII
6. LYB
7. LITE
8. NVT
9. SPY
10. AAPL

Go back to Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer

Chiasma Reports Fourth Quarter and Year End 2015 Results

March 14, 2016 4:01 PM EDT

Initiates Pivotal EU Phase 3 Trial

Expands Organization in Advance of PDUFA Date

Provides Operating Expense Guidance for 2016

NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a late-stage biopharmaceutical company developing Mycapssa (octreotide) capsules, an investigational new oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2015.

Chiasma made significant progress from a clinical, regulatory, financial and organizational standpoint in... More